Rec'd PCT/PTO 25 FEB 2002

FORM PTO-1390 (Modified)
(REV 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER
219183US0XPCT

U.S. APPLICATION NO. (IF KNOWN. SEE 37 CFR
10/049642

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/EP00/06506	**08 JULY 2000**	**24 AUGUST 1999**

TITLE OF INVENTION

COPOLYMERS OF AMINOPROPYL VINYL ETHER

APPLICANT(S) FOR DO/EO/US

Peter OTTERSBACH, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include itens (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
   a. ☐ is attached hereto (required only if not communicated by the International Bureau).
   b. ☒ has been communicated by the International Bureau.
   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
   a. ☒ is attached hereto.
   b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
   a. ☐ are attached hereto (required only if not communicated by the International Bureau).
   b. ☐ have been communicated by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☒ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☐ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

    Notice of Priority / PCT/IB/308 / PTO-1449

PCTUS1/REV03

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
10/049642	PCT/EP00/06506	219183US0XPCT

24. The following fees are submitted:.	CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :		
☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO **$1040.00**		
☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **$890.00**		
☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **$740.00**		
☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) **$710.00**		
☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) **$100.00**		
ENTER APPROPRIATE BASIC FEE AMOUNT =	**$890.00**	
Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).	**$0.00**	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	22 - 20 =	2	x $18.00	**$36.00**	
Independent claims	4 - 3 =	1	x $84.00	**$84.00**	
Multiple Dependent Claims **(check if applicable)**.			☐	**$0.00**	
TOTAL OF ABOVE CALCULATIONS =				**$1,010.00**	
☐ Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				**$0.00**	
SUBTOTAL =				**$1,010.00**	
Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +				**$0.00**	
TOTAL NATIONAL FEE =				**$1,010.00**	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) **(check if applicable).** ☐				**$0.00**	
TOTAL FEES ENCLOSED =				**$1,010.00**	
				Amount to be: refunded	$
				charged	$

a. ☒ A check in the amount of **$1,010.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **15-0030** A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

22850

(703) 413-3000

Surinder Sachar
Registration No. 34,423

Surinder Sachar
SIGNATURE

Norman F. Oblon
NAME

24,618
REGISTRATION NUMBER

Feb. 25 2002
DATE

Docket No. 219183US0X PCT

IN RE APPLICATION OF: Peter OTTERSBACH, et al.

SERIAL NO: NEW U.S. PCT APPLICATION BASED ON PCT/EP00/06506

FILED: HEREWITH

FOR: COPOLYMERS OF AMINOPROPYL VINYL ETHER

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Transmitted herewith is an amendment in the above-identified application.

☒ No additional fee is required

☐ Small entity status of this application under 37 C.F.R. §1.9 and §1.27 is claimed.

☒ Additional documents filed herewith: English Translation of Specification/Request for Priority/PCT Transmittal Letter
PTO-1449/Information Disclosure Statement/International Search Report
Amended Specification (24 pages)/Declaration/Preliminary Amendment
PCT/IB/308/Check for $1,010.00

The Fee has been calculated as shown below:

CLAIMS	CLAIMS REMAINING		HIGHEST NUMBER PREVIOUSLY PAID	NO. EXTRA CLAIMS	RATE	CALCULATIONS
TOTAL	22	MINUS	22	0	× $18 =	$0.00
INDEPENDENT	4	MINUS	4	0	× $84 =	$0.00
		☐ MULTIPLE DEPENDENT CLAIMS			+ $280 =	$0.00
		TOTAL OF ABOVE CALCULATIONS				$0.00
		☐ Reduction by 50% for filing by Small Entity				$0.00
		☐ Recordation of Assignment			+ $40 =	$0.00
		TOTAL				$0.00

☐ A check in the amount of **$0.00** is attached.

☒ Please charge any additional Fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

☒ If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. §1.136, and any additional fees required under 37 C.F.R. §1.136 for any necessary extension of time may be charged to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

22850
Customer Number 22850
Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 10/01)

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon
Registration No. 24,618

Surinder Sachar
Registration No. 34,423

#4
a

219183US-0XPCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF: :

PETER OTTERSBACH ET AL : ATTN: APPLICATION DIVISION

SERIAL NO: NEW U.S. PCT APPLN :
(Based on PCT/EP00/06506)

FILED: HEREWITH :

FOR: COPOLYMERS OF AMINOPROPYL :
VINYL ETHER

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as follows:

IN THE CLAIMS

Please cancel Claims 19-22.

Please amend the claims as shown in the marked-up copy following this amendment to read as follows:

1. (Amended) An antimicrobial copolymer, obtained by copolymerizing a vinyl ether of formula



where R^1 is a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, and

R^2 is H, and

R^3 is H or a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms,

with at least one aliphatically unsaturated monomer.

2. (Amended) The antimicrobial polymer as claimed in claim 1, wherein the vinyl ether comprises 3-aminopropyl vinyl ether.

3. (Amended) The antimicrobial polymer as claimed in claim 1, wherein the aliphatically unsaturated monomer is a methacrylic acid compound.

4. (Amended) The antimicrobial polymer as claimed in claim 1, wherein the aliphatically unsaturated monomer is an acrylic acid compound.

5. (Amended) The antimicrobial polymer as claimed in claim 1, wherein the aliphatically unsaturated monomer is methyl methacrylate, ethyl methacrylate, butyl methacrylate, tert-butyl methacrylate, methyl acrylate, ethyl acrylate, butyl acrylate, tert-butyl acrylate, tert-butylaminoethyl esters, 2-diethylaminoethyl methacrylate, 2-diethyl-aminoethyl vinyl ether, N-3-dimethylamino-propylmethacrylamide, 3-methacryloyl-aminopropyl-trimethylammonium chloride, 2-methacryloyloxyethyltrimethylammonium chloride or 2-methacryloyloxyethyltrimethylammonium methosulfate.

6. (Amended) The antimicrobial polymer as claimed in claim 1, wherein the copolymerization is carried out on a substrate.

7. (Amended) An antimicrobial coating of a substrate, wherein at least one vinyl ether of formula



where R^1 is a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, and

R^2 and R^3 are H or a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, where R^2 and R^3 may be identical or different,

are copolymerized in a graft polymerization of a substrate.

8. (Amended) The antimicrobial coating as claimed in claim 7, wherein the substrate is activated prior to the graft polymerization by UV radiation, plasma treatment, corona treatment, flame treatment, ozonization, electrical discharge or γ-radiation.

9. (Amended) The antimicrobial coating as claimed in claim 7, wherein the substrate is activated, prior to the graft polymerization, by UV radiation with a photoinitiator.

10. (Amended) A process for preparing an antimicrobial copolymer, which comprises copolymerizing a vinyl ether of formula



where R^1 is a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms,

R^2 is H, and

R^3 is H or a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms,

with at least one aliphatically saturated monomer.

11. (Amended) The process as claimed in claim 10, wherein

the vinyl ether comprises 3-aminopropyl vinyl ether.

12. (Amended) The process as claimed in claim 10, wherein

the aliphatically unsaturated monomer is a methacrylic acid compound.

13. (Amended) The process as claimed in claim 10, wherein

the aliphatically unsaturated monomer is an acrylic acid compound.

14. (Amended) The process as claimed in claim 10, wherein

the aliphatically unsaturated monomer is methyl methacrylate, ethyl methacrylate, butyl methacrylate, tert-butyl methacrylate, methyl acrylate, ethyl acrylate, butyl acrylate, tert-butyl acrylate, tert-butylaminoethyl esters, 2-diethylaminoethyl methacrylate, 2-diethylamino-ethyl vinyl ether, N-3-dimethylaminopropyl-methacrylamide, 3-methacryloylaminopropyltrimethylammonium chloride, 2-

methacryloyloxyethyltrimethylammonium chloride or 2-methacryloyloxyethyltrimethylammonium methosulfate.

15. (Amended) The process as claimed in claim 10, wherein the copolymerization is carried out on a substrate.

16. (Amended) A process for preparing an antimicrobial coating of a substrate, which comprises

copolymerizing at least one vinyl ether of formula



where R^1 is a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, and

R^2 and R^3 are H or a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, where R^2 and R^3 may be identical or different,

in a graft polymerization of a substrate.

Please add the following new claims:

23. (New) A process for producing a product with an antimicrobial coating, said process comprising

coating said product with the antimicrobial polymer claimed in Claim 1.

24. (New) A process for producing a medical device with an antimicrobial coating, said process comprising

coating said medical device with the antimicrobial polymer claimed in Claim 1.

25. (New) A process for producing a hygiene article with an antimicrobial coating, said process comprising

coating said hygiene article with the antimicrobial polymer claimed in Claim 1.

26. (New) A process of producing a surface coating, protective paint or other coating, said process comprising

incorporating the antimicrobial polymer claimed in Claim 1 in said surface coating, protective paint or other coating.

REMARKS

Claims 1-18 and 23-26 are active in the present application. Claims 19-22 have been cancelled. Claims 23-26 are new claims. Support for the new claims is found in the original claims. Claims 1-18 have been amended for clarity and to remove multiple dependencies. No new matter is believed to have been added by this amendment. An action on the merits and allowance of claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Stefan U. Koschmieder, Ph.D.
Registration No.ρ 50,238

(703) 413-3000
Fax #: (703)413-2220
NFO:SUK\la
I:\atty\SUKOS\219183us-pr.wpd

Marked-Up Copy
Serial No: _____
Amendment Filed on:
2-25-2002

IN THE CLAIMS

Claims 19-22 (Cancelled).

Please amend the claims as follows:

--1. (Amended) An antimicrobial copolymer, [obtainable] obtained by copolymerizing a vinyl ether of [the general] formula



where R^1 is a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, and

R^2 is H, and

R^3 is H or a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms,

with at least one aliphatically unsaturated monomer.

2. (Amended) [An] The antimicrobial polymer as claimed in claim 1, wherein the vinyl ether [used] comprises 3-aminopropyl vinyl ether.

3. (Amended) [An] The antimicrobial polymer as claimed in claim 1 [or 2], wherein

the aliphatically unsaturated [monomers are] monomer is a methacrylic acid [compounds] compound.

4. (Amended) [An] The antimicrobial polymer as claimed in claim 1 [or 2], wherein

the aliphatically unsaturated [monomers are] monomer is an acrylic acid [compounds] compound.

5. (Amended) [An] The antimicrobial polymer as claimed in claim 1 [or 2], wherein

the aliphatically unsaturated [monomers used are] monomer is methyl methacrylate, ethyl methacrylate, butyl methacrylate, tert-butyl methacrylate, methyl acrylate, ethyl acrylate, butyl acrylate, tert-butyl acrylate, tert-butylaminoethyl esters, 2-diethylaminoethyl methacrylate, 2-diethyl-aminoethyl vinyl ether, N-3-dimethylamino-propylmethacrylamide, 3-methacryloyl-aminopropyl-trimethylammonium chloride, 2-methacryloyloxyethyltrimethylammonium chloride or 2-methacryloyloxyethyltrimethylammonium methosulfate.

6. (Amended) [An] The antimicrobial polymer as claimed in [any one of claims 1 to 5] claim 1, wherein

the copolymerization is carried out on a substrate.

7. (Amended) An antimicrobial coating of a substrate, wherein at least one vinyl ether [ethers] of [the general] formula



where R^1 is a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, and

R^2 and R^3 are H [II] or a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, where R^2 and R^3 may be identical or different,

are copolymerized in a graft polymerization of a substrate.

8. (Amended) [An] The antimicrobial coating as claimed in claim 7, wherein

the substrate is activated prior to the graft polymerization by UV radiation, plasma treatment, corona treatment, flame treatment, ozonization, electrical discharge or γ-radiation.

9. (Amended) [An] The antimicrobial coating as claimed in claim 7, wherein

the substrate is activated, prior to the graft polymerization, by UV radiation with a photoinitiator.

10. (Amended) A process for preparing an antimicrobial [copolymers] copolymer, which comprises copolymerizing a vinyl ether of [the general] formula



where R^1 is a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms,

R^2 is H, and

R^3 is H or a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms,

with at least one aliphatically saturated monomer.

11. (Amended) The process as claimed in claim 10, wherein

the vinyl ether [used] comprises 3-aminopropyl vinyl ether.

12. (Amended) The process as claimed in claim 10 [or 11], wherein

the aliphatically unsaturated [monomers are] monomer is a methacrylic acid [compounds] compound.

13. (Amended) The process as claimed in claim 10 [or 11], wherein

the aliphatically unsaturated [monomers are] monomer is an acrylic acid [compounds] compound.

14. (Amended) The process as claimed in claim 10 [or 11], wherein

the aliphatically unsaturated [monomers used are] monomer is methyl methacrylate, ethyl methacrylate, butyl methacrylate, tert-butyl methacrylate, methyl acrylate, ethyl acrylate, butyl acrylate, tert-butyl acrylate, tert-butylaminoethyl esters, 2-diethylaminoethyl methacrylate, 2-diethylamino-ethyl vinyl ether, N-3-dimethylaminopropyl-methacrylamide, 3-methacryloylaminopropyltrimethylammonium chloride, 2-methacryloyloxyethyltrimethylammonium chloride or 2-methacryloyloxyethyltrimethylammonium methosulfate.

15. (Amended) The process as claimed in [any one of claims 10 to 14] claim 10, wherein

the copolymerization is carried out on a substrate.

16. (Amended) A process for preparing an antimicrobial coating of a substrate, [wh..ch] which comprises

copolymerizing at least one vinyl ether [ethers] of [the general] formula



where R^1 is a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, and

R^2 and R^3 are H or a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, where R^2 and R^3 may be identical or different,

in a graft polymerization of a substrate.--

Claims 23-26 (New).

THE FOLLOWING IS THE ENGLISH TRANSLATION OF THE SUBSTITUTE SPECIFICATION: 24 Pages

Copolymers of aminopropyl vinyl ether

The invention relates to antimicrobial polymers obtained by copolymerizing aminofunctionalized vinyl ethers with other monomers. The invention further relates to a process for preparing these antimicrobial polymers, and to their use.

The invention further relates to antimicrobial polymers obtained by a graft copolymerization of aminofunctionalized vinyl ethers with other monomers on a substrate, and also to a process for the preparation of the graft copolymers, and to their use.

It is highly undesirable for bacteria to become established or to spread on the surfaces of pipelines, containers or packaging. Frequently, slime layers form and permit sharp rises in microbial populations, and these can lead to persistent impairment of the quality of water, drinks or foods, and even to spoilage of the product and harm to the health of consumers.

Bacteria must be kept away from all areas of life in which hygiene is important. This affects textiles for direct body contact, especially in the genital area, and for the care of the elderly and sick. Bacteria must also be kept away from surfaces of furniture and instruments in wards, especially in areas for intensive care and neonatal care, in hospitals, especially in areas for medical interventions, and in isolation wards for critical cases of infection, and also in toilets.

A current method of treating equipment, or the surfaces of furniture or textiles, to resist bacteria, either when this becomes necessary or else as a precautionary measure, is to use chemicals or solutions or mixtures of these which as disinfectants have fairly broad and general antimicrobial action. Chemical agents of this type act nonspecifically and are frequently themselves

toxic or irritant, or form degradation products which are hazardous to health. In addition, people frequently exhibit intolerance to these materials once they have become sensitized.

Another method to counteract surface spread of bacteria is to incorporate substances with antimicrobial action into a matrix.

tert-Butylaminoethyl methacrylate is a commercially available monomer in methacrylate chemistry and is used in particular as a hydrophilic constituent in copolymerizations. For example, EP-B 0 290 676 describes the use of various polyacrylates and polymethacrylates as a matrix for immobilizing bactericidal quaternary ammonium compounds.

In another technical sector US-A 4 532 269 discloses a terpolymer of butyl methacrylate, tributyltin methacrylate and tert-butylaminoethyl methacrylate. This polymer is used as an antimicrobial paint for ships: the hydrophilic tert-butylaminoethyl methacrylate promotes gradual erosion of the polymer, thus liberating the highly toxic tributyltin methacrylate as antimicrobial agent.

In these applications the copolymer prepared using aminomethacrylates is merely a matrix or carrier substance for added microbicidal agents which can diffuse or migrate out of the carrier substance. Sooner or later, polymers of this type lose their effectiveness once the "minimal inhibitory concentration" (MIC) is no longer achieved on the surface.

European Patent Applications 0 862 858 and 0 862 859 have disclosed that homo- and copolymers of tert-butylaminoethyl methacrylate, a methacrylate having a secondary amino function, have inherent microbicidal

properties. To avoid undesirable resistance phenomena in the microbes, particularly bearing in mind the development of resistance by bacteria known from antibiotics research, systems developed in the future will also have to be based on novel compositions with improved effectiveness.

US 2 980 634 discloses antimicrobial polymers based on vinyl ethers and having a tertiary amino function. These polymers may be quaternized before or after polymerization.

The object of the present invention is therefore to develop novel polymers having antimicrobial action which prevent the establishment and spread of bacteria on surfaces.

Surprisingly, it has now been found that copolymerizing aminofunctionalized vinyl ethers with aliphatically unsaturated monomers and, respectively, a graft copolymerization of these components on a substrate gives polymers with a surface which is durably microbicidal, resists solvents and physical stresses and does not exhibit migration. This means that there is no need for other biocides to be used.

3-Aminopropyl vinyl ether is a commercially available product whose preparation can be found, for example, in the European Patent Application 0 514 710. It is used, inter alia, as an additive for photoresist systems, described, for example, in US 5648194, or as an element in the structure of adhesion promoters in specific urethane-silanes, described, for example, in US 5384342. The use of compounds of this type in antimicrobial polymers is not known.

The present invention therefore provides antimicrobial copolymers which are obtained by copolymerizing a vinyl ether of the general formula



where R^1 is a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms,
R^2 is H, and
R^3 is H or a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms,

with at least one aliphatically unsaturated monomer.

The proportion of vinyl ethers in the reaction mixture should be from 5 to 98 mol%, preferably from 30 to 98 mol%, particularly preferably from 50 to 98 mol%, based on the total of the monomers, in order to obtain sufficient antimicrobial action from the polymer.

The aliphatically unsaturated monomers used may be any monomers which enter into copolymerization with the vinyl ethers of the general formula. Examples of suitable monomers are acrylates or methacrylates, such as acrylic acid, tert-butyl methacrylate or methyl methacrylate, styrene, vinyl chloride, vinyl ethers, acrylamides, acrylonitriles, olefins (ethylene, propylene, butylene or isobutylene), allyl compounds, vinyl ketones, vinyl acetic acid, vinyl acetate or vinyl esters, in particular, for example, methyl methacrylate, ethyl methacrylate, butyl methacrylate, tert-butyl methacrylate, methyl acrylate, ethyl acrylate, butyl acrylate, tert-butyl acrylate, tert-butylaminoethyl esters, 2-diethylaminoethyl methacrylate, 2-diethylaminoethyl vinyl ether, N-3-diethylaminopropylmethacrylamide, 3-methacryloyl-

aminopropyltrimethylammonium chloride, 2-methacryloyl-oxyethyltrimethylammonium chloride or 2-methacryloyl-oxyethyltrimethylammonium methosulfate.

The aliphatically unsaturated monomers are preferably acrylic acid compounds or methacrylic acid compounds, and the vinyl ethers of the general formula are preferably 3-aminopropyl vinyl ether.

The novel antimicrobial copolymers may be obtained by copolymerizing vinyl ethers of the general formula, in particular 3-aminopropyl vinyl ethers with one or more aliphatically unsaturated monomers. The polymerization is usefully a free-radical polymerization using a free-radical initiator or induced by radiation. Typical procedures are described in the examples.

The novel antimicrobial copolymers may also be obtained by copolymerizing vinyl ethers of the general formula, in particular 3-aminopropyl vinyl ether with at least one aliphatically unsaturated monomer on a substrate. This gives a physisorbed coating of the antimicrobial copolymer on the substrate.

Suitable substrate materials are especially any of the polymeric plastics, such as polyurethanes, polyamides, polyesters or polyethers, polyether block amides, polystyrene, polyvinyl chloride, polycarbonates, poly-organosiloxanes, polyolefins, polysulfones, polyisoprene, polychloroprene, polytetrafluoroethylene (PTFE) or corresponding copolymers or blends, or else naturally occurring or synthetic rubbers, with or without radiation-sensitive groups. The novel process may also be used on the surfaces of objects made from metal, from glass or from wood and surface-coated or otherwise coated with plastic.

In another embodiment of the present invention the copolymers may be prepared by a graft polymerization of a substrate with vinyl ethers of the general formula



where R^1 is a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, and R^2 and R^3 are H or a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, where R^2 and R^3 may be identical or different,

in particular with 3-aminopropyl vinyl ether, and with at least one aliphatically unsaturated monomer. The grafting of the substrate allows covalent linking of the antimicrobial copolymer to the substrate. Substrates which may be used are any polymeric material, such as the plastics mentioned above.

Prior to the graft copolymerization, the surfaces of the substrate may be activated by a variety of methods. Any standard method for activating polymer surfaces may be used here, for example the substrate may be activated prior to the graft polymerization by UV radiation, plasma treatment, corona treatment, flame treatment, ozonization, electrical discharge or γ-radiation. The surfaces are usefully freed in advance in a known manner from oils, fats or other contamination, using a solvent.

The substrates may be activated using UV radiation in the wavelength range from 170 to 400 nm, preferably

from 170 to 250 nm. An example of a suitable radiation source is a Noblelight UV excimer apparatus from HERAEUS, Hanau, Germany. However, mercury vapor lamps are also suitable for substrate activation as long as they emit substantial proportions of radiation in the abovementioned ranges. The exposure time is generally from 0.1 seconds to 20 minutes, preferably from 1 second to 10 minutes.

The activation of the substrate with UV radiation prior to the graft polymerization may also be done using an additional photosensitizer. For this, the photosensitizer, such as benzophenone, is applied to the substrate surface and irradiated. A mercury vapor lamp may again be used here, with exposure times of from 0.1 second to 20 minutes, preferably from 1 second to 10 minutes.

According to the invention, the activation may also be achieved by plasma treatment using an RF or microwave plasma (Hexagon, Technics Plasma, 85551 Kirchheim, Germany) in air, nitrogen or argon atmospheres. The exposure times are generally from 2 seconds to 30 minutes, preferably from 5 seconds to 10 minutes. The energy supplied in the case of laboratory devices is from 100 to 500 W, preferably from 200 to 300 W.

Corona devices (SOFTAL, Hamburg, Germany) may also be used for activation. The exposure times in this case are generally from 1 to 10 minutes, preferably from 1 to 60 seconds.

Activation by electrical discharge, electron beam or γ-radiation (e.g. from a cobalt 60 source), and also ozonization, allows short exposure times, generally from 0.1 to 60 seconds.

Substrate surfaces may also be activated by flame treatment. Suitable devices, in particular those with a

barrier flame front, can readily be constructed or, for example, purchased from ARCOTEC, 71297 Mönsheim, Germany. They may be operated using hydrocarbons or hydrogen as combustion gas. In all cases it is necessary to avoid damage to the substrate by overheating, and this can readily be ensured if the surface of the substrate facing away from the flame treatment side is in intimate contact with a cooled metal surface. Activation by flame treatment is therefore restricted to relatively thin, sheet-like substrates. The exposure times are generally from 0.1 second to 1 minute, preferably from 0.5 to 2 seconds. The flames are exclusively nonluminous, and the distances between the substrate surfaces and the outer side of the flame front are from 0.2 to 5 cm, preferably from 0.5 to 2 cm.

The substrate surfaces activated in this way are coated by known methods, such as dipping, spraying or spreading, with vinyl ethers of the general formula (component I), in particular with 3-aminopropyl vinyl ether, and with one or more aliphatically unsaturated monomers (component II), in solution if desired. Solvents which have proven useful are water and water/ethanol mixtures, but other solvents may also be used as long as they are sufficiently capable of dissolving the monomers and give good wetting of the substrate surfaces. Solutions with monomer contents of from 1 to 10% by weight, for example about 5% by weight, have proven successful in practice and generally give, in a single pass, coherent coatings which cover the substrate surface and have thicknesses which can be more than 0.1 µm.

The graft copolymerization of the monomers applied to the activated surfaces may usefully be initiated by radiation in the short-wave segment of the visible range or in the long-wave segment of the UV range of electromagnetic radiation. For example, the radiation

from a UV excimer of wavelengths from 250 to 500 nm, preferably from 290 to 320 nm, is very suitable. Mercury vapor lamps are also suitable here as long as they have substantial proportions of radiation in the abovementioned ranges. The exposure times are generally from 10 seconds to 30 minutes, preferably from 2 to 15 minutes.

A graft copolymerization of the novel comonomer compounds can also be achieved by a process described in European Patent Application 0 872 512 and based on a graft polymerization of monomer molecules and initiator molecules incorporated by swelling. The monomer used for the swelling may be component II.

Even without grafting onto a substrate surface, the novel antimicrobial copolymers of vinyl ethers of the general formula (component I), in particular 3-aminopropyl vinyl ether with at least one aliphatically unsaturated monomer (component II) show microbicidal or antimicrobial behaviour. Another embodiment of the present invention consists in carrying out the copolymerization of components I and II on a substrate.

The components may be in solution when applied to the substrate. Examples of suitable solvents are water, ethanol, methanol, methyl ethyl ketone, diethyl ether, dioxane, hexane, heptane, benzene, toluene, chloroform, dichloromethane, tetrahydrofuran and acetonitrile. It is also possible to use component II as solvent for component I.

The novel antimicrobial copolymers may also be used directly, i.e. not by polymerizing the components on a substrate but as an antimicrobial coating. Suitable coating methods are application of the copolymers in solution or as a melt.

The solution of the novel polymers may be applied to the substrates by dipping, spraying or painting, for example.

If the novel polymers are used directly on the substrate surface without grafting, conventional free-radical initiators may be added.

Examples of initiators which may be used in the preparation of the novel copolymers are, inter alia, azonitriles, alkyl peroxides, hydroperoxides, acyl peroxides, peroxoketones, peresters, peroxocarbonates, peroxodisulfate, persulfate and any of the usual photoinitiators, such as acetophenones, α-hydroxyketones, dimethylketals and benzophenone. The polymerization may also be initiated thermally or, as already stated, by electromagnetic radiation, such as UV light or γ-radiation.

The novel antimicrobial polymers may also be used as components for formulating inks, paints or other surface coatings.

Use of the modified polymer substrates

The present invention also provides the use of the novel antimicrobial polymers to produce antimicrobially active products, and the products per se which are produced in this way. The products may comprise polymer substrates modified according to the invention or consist of these. Products of this type are preferably based on polyamides, polyurethanes, polyether block amides, polyesteramides or -imides, PVC, polyolefins, silicones, polysiloxanes, polymethacrylate or poly-terephthalates which are surface-modified using novel polymers.

Examples of antimicrobially active products of this type are in particular machine parts for food processing, components in air-conditioning systems,

roofing, items for bathroom and toilet use, kitchen items, components of sanitary equipment, components of cages or houses for animals, recreational products for children, components of water systems, food packaging, operator units (touch panels) of devices, and contact lenses.

The novel copolymers or graft copolymers may be used anywhere where importance is placed on surfaces with release properties or surfaces which are very free from bacteria, i.e. microbicidal. Examples of application of the novel copolymers or graft polymers are in particular surface coatings, protective paints and other coatings in the following sectors:

- Marine: Boat hulls, docks, buoys, drilling platforms, ballast water tanks
- Construction: Roofing, basements, walls, facades, greenhouses, sun protection, garden fencing, wood protection
- Sanitary: Public conveniences, bathrooms, shower curtains, toilet items, swimming pool, sauna, jointing, sealing compounds
- Requisites for daily life: Machines, kitchen, kitchen items, sponge pads, recreational products for children, food packaging, milk processing, drinking water systems, cosmetics
- Machine parts: Air-conditioning systems, ion exchangers, process water, solar-powered units, heat exchangers, bioreactors, membranes
- Medical technology: Contact lenses, diapers, membranes, implants
- Consumer articles: Automobile seats, clothing (socks, sports clothing), hospital equipment, door handles, telephone handsets, public conveyances, animal cages, cash registers, wall-to-wall carpets, wallpapers.

The present invention also provides for the use of the novel polymer substrates, whose surfaces have been modified using novel polymers or processes, for producing hygiene products or items in medical technology. That which has been said above concerning preferred materials applies correspondingly. Examples of hygiene products of this type are toothbrushes, toilet seats, combs and packaging materials. The term hygiene item also includes other objects which may come into contact with a large number of people, such as telephone handsets, stair rails, door handles, window catches, and grab straps and grab handles in public conveyances. Examples of items in medical technology are catheters, tubing, protective or backing films and also surgical instruments.

The following examples are given in order to describe the present invention in greater detail, but are not intended to limit its scope as set out in the patent claims.

Example 1:

6 g of 3-aminopropyl vinyl ether (Aldrich), 6 g of methyl methacrylate (Aldrich) and 60 ml of ethanol are charged to a three-necked flask and heated to 65°C under a stream of argon. 0.15 g of azobisisobutyronitrile dissolved in 4 ml of ethyl methyl ketone is then slowly added dropwise, with stirring. The mixture is heated to 70°C and stirred at this temperature for 72 h. After expiry of this time the reaction mixture is stirred into 0.5 l of deionized water, whereupon the polymeric product precipitates. After filtering off the product, the filter cake is washed with 100 ml of deionized water to remove any monomer residues still present. The product is then dried in vacuo for 24 hours at 50°C.

Example 1a:

0.05 g of the product from Example 1 is shaken in 20 ml of a test microbial suspension of Staphylococcus aureus. After a contact time of 15 minutes, 1 ml of the test microbial suspension is removed, and the number of microbes in the test mixture is determined. After expiry of this time Staphylococcus aureus microbes are no longer detectable.

Example 1b:

0.05 g of the product from Example 1 is shaken in 20 ml of a test microbial suspension of Pseudomonas aeruginosa. After a contact time of 60 minutes, 1 ml of the test microbial suspension is removed, and the number of microbes in the test mixture is determined. After expiry of this time the number of microbes has reduced from 10^7 to 10^2.

Example 2:

6 g of 3-aminopropyl vinyl ether (Aldrich), 6 g of butyl methacrylate (Aldrich) and 60 ml of ethanol are charged to a three-necked flask and heated to 65°C under a stream of argon. 0.15 g of azobisisobutyronitrile dissolved in 4 ml of ethyl methyl ketone is then slowly added dropwise, with stirring. The mixture is heated to 70°C and stirred at this temperature for 72 h. After expiry of this time the reaction mixture is stirred into 0.5 l of deionized water, whereupon the polymeric product precipitates. After filtering off the product, the filter cake is washed with 100 ml of deionized water to remove any monomer residues still present. The product is then dried in vacuo for 24 hours at 50°C.

Example 2a:

0.05 g of the product from Example 2 is shaken in 20 ml of a test microbial suspension of Staphylococcus aureus. After a contact time of 15 minutes, 1 ml of the test microbial suspension is removed, and the

number of microbes in the test mixture is determined. After expiry of this time Staphylococcus aureus microbes are no longer detectable.

Example 2b:

0.05 g of the product from Example 2 is shaken in 20 ml of a test microbial suspension of Pseudomonas aeruginosa. After a contact time of 60 minutes, 1 ml of the test microbial suspension is removed, and the number of microbes in the test mixture is determined. After expiry of this time the number of microbes has reduced from 10^7 to 10^2.

Example 3:

6 g of 3-aminopropyl vinyl ether (Aldrich), 6 g of 2-diethylaminoethyl methacrylate (Aldrich) and 60 ml of ethanol are charged to a three-necked flask and heated to 65°C under a stream of argon. 0.15 g of azobisisobutyronitrile dissolved in 4 ml of ethyl methyl ketone is then slowly added dropwise, with stirring. The mixture is heated to 70°C and stirred at this temperature for 72 h. After expiry of this time the reaction mixture is stirred into 0.5 l of deionized water, whereupon the polymeric product precipitates. After filtering off the product, the filter cake is washed with 100 ml of deionized water to remove any monomer residues still present. The product is then dried in vacuo for 24 hours at 50°C.

Example 3a:

0.05 g of the product from Example 3 is shaken in 20 ml of a test microbial suspension of Staphylococcus aureus. After a contact time of 15 minutes, 1 ml of the test microbial suspension is removed, and the number of microbes in the test mixture is determined. After expiry of this time the number of microbes has reduced from 10^7 to 10^2.

Example 3b:

0.05 g of the product from Example 3 is shaken in 20 ml of a test microbial suspension of Pseudomonas aeruginosa. After a contact time of 60 minutes, 1 ml of the test microbial suspension is removed, and the number of microbes in the test mixture is determined. After expiry of this time the number of microbes has reduced from 10^7 to 10^2.

Example 4:

6 g of 3-aminopropyl vinyl ether (Aldrich), 6 g of tert-butyl methacrylate (Aldrich) and 60 ml of ethanol are charged to a three-necked flask and heated to 65°C under a stream of argon. 0.15 g of azobis-isobutyronitrile dissolved in 4 ml of ethyl methyl ketone is then slowly added dropwise, with stirring. The mixture is heated to 70°C and stirred at this temperature for 72 h. After expiry of this time the reaction mixture is stirred into 0.5 l of deionized water, whereupon the polymeric product precipitates. After filtering off the product, the filter cake is washed with 100 ml of deionized water to remove any monomer residues still present. The product is then dried in vacuo for 24 hours at 50°C.

Example 4a:

0.05 g of the product from Example 4 is shaken in 20 ml of a test microbial suspension of Staphylococcus aureus. After a contact time of 15 minutes, 1 ml of the test microbial suspension is removed, and the number of microbes in the test mixture is determined. After expiry of this time Staphylococcus aureus microbes are no longer detectable.

Example 4b:

0.05 g of the product from Example 4 is shaken in 20 ml of a test microbial suspension of Pseudomonas aeruginosa. After a contact time of 60 minutes, 1 ml of the test microbial suspension is removed, and the

number of microbes in the test mixture is determined. After expiry of this time the number of microbes has reduced from 10^7 to 10^2.

Example 5:

A nylon-12 film is exposed for 2 minutes at a pressure of 1 mbar to 172 nm radiation from a Heraeus excimer source. The film activated in this way is placed into an irradiator under an inert gas and secured. Under a counterstream of inert gas, the film is then covered with 20 ml of a mixture of 6 g of 3-aminopropyl vinyl ether (Aldrich), 6 g of butyl methacrylate (Aldrich) and 60 g of ethanol. The irradiation chamber is sealed and placed at a distance of 10 cm from a Heraeus excimer source emitting at wavelength 308 nm. Irradiation is begun and continues for 15 minutes. The film is then removed and rinsed with 30 ml of ethanol. The film is then dried for 12 hours at 50°C in vacuo. The film is then extracted in water for 5 times 6 hours at 30°C, then dried for 12 hours at 50°C.

The reverse side of the film is then treated in the same way, so that the nylon film finally obtained has been coated on both sides with grafted polymer.

Example 5a:

A piece of coated film from Example 5 (5 x 4 cm) is shaken in 30 ml of a test microbial suspension of Staphylococcus aureus. After a contact time of 15 minutes, 1 ml of the test microbial suspension is removed and the number of microbes in the test mixture is determined. After expiry of this time Staphylococcus aureus microbes are no longer detectable.

Example 5b:

A piece of coated film from Example 5 (5 x 4 cm) is shaken in 30 ml of a test microbial suspension of Pseudomonas aeruginosa. After a contact time of 60 minutes, 1 ml of the test microbial suspension is

removed and the number of microbes in the test mixture is determined. After expiry of this time the number of microbes has reduced from 10^7 to 10^4.

Example 6:

A nylon-12 film is exposed for 2 minutes at a pressure of 1 mbar to 172 nm radiation from a Heraeus excimer source. The film activated in this way is placed into an irradiator under an inert gas and secured. Under a counterstream of inert gas, the film is then covered with 20 ml of a mixture of 6 g of 3-aminopropyl vinyl ether (Aldrich), 4 g of tert-butyl methacrylate (Aldrich) and 60 g of ethanol. The irradiation chamber is sealed and placed at a distance of 10 cm from a Heraeus excimer source emitting at wavelength 308 nm. Irradiation is begun and continues for 15 minutes. The film is then removed and rinsed with 30 ml of ethanol. The film is then dried for 12 hours at 50°C in vacuo. The film is then extracted in water for 5 times 6 hours at 30°C, then dried for 12 hours at 50°C.

The reverse side of the film is then treated in the same way, so that the nylon film finally obtained has been coated on both sides with grafted polymer.

Example 6a:

A piece of coated film from Example 6 (5 x 4 cm) is shaken in 30 ml of a test microbial suspension of Staphylococcus aureus. After a contact time of 15 minutes, 1 ml of the test microbial suspension is removed and the number of microbes in the test mixture is determined. After expiry of this time Staphylococcus aureus microbes are no longer detectable.

Example 6b:

A piece of coated film from Example 6 (5 x 4 cm) is shaken in 30 ml of a test microbial suspension of Pseudomonas aeruginosa. After a contact time of 60 minutes, 1 ml of the test microbial suspension is

removed and the number of microbes in the test mixture is determined. After expiry of this time the number of microbes has reduced from 10^7 to 10^4.

What is claimed is:

1. An antimicrobial copolymer, obtainable by copolymerizing a vinyl ether of the general formula



where R^1 is a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, and
R^2 is H, and
R^3 is H or a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms,

with at least one aliphatically unsaturated monomer.

2. An antimicrobial polymer as claimed in claim 1, wherein
the vinyl ether used comprises 3-aminopropyl vinyl ether.

3. An antimicrobial polymer as claimed in claim 1 or 2, wherein
the aliphatically unsaturated monomers are methacrylic acid compounds.

4. An antimicrobial polymer as claimed in claim 1 or 2,

wherein
the aliphatically unsaturated monomers are acrylic acid compounds.

5. An antimicrobial polymer as claimed in claim 1 or 2,
wherein
the aliphatically unsaturated monomers used are methyl methacrylate, ethyl methacrylate, butyl methacrylate, tert-butyl methacrylate, methyl acrylate, ethyl acrylate, butyl acrylate, tert-butyl acrylate, tert-butylaminoethyl esters, 2-diethylaminoethyl methacrylate, 2-diethylaminoethyl vinyl ether, N-3-dimethylaminopropylmethacrylamide, 3-methacryloylaminopropyltrimethylammonium chloride, 2-methacryloyloxyethyltrimethylammonium chloride or 2-methacryloyloxyethyltrimethylammonium methosulfate.

6. An antimicrobial polymer as claimed in any one of claims 1 to 5,
wherein
the copolymerization is carried out on a substrate.

7. An antimicrobial coating of a substrate,
wherein
vinyl ethers of the general formula



where R^1 is a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, and
R^2 and R^3 are H or a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, where R^2 and R^3 may be identical or different,

are copolymerized in graft polymerization of a substrate.

8. An antimicrobial coating as claimed in claim 7, wherein
the substrate is activated prior to the graft polymerization by UV radiation, plasma treatment, corona treatment, flame treatment, ozonization, electrical discharge or γ-radiation.

9. An antimicrobial coating as claimed in claim 7, wherein
the substrate is activated, prior to the graft polymerization, by UV radiation with a photoinitiator.

10. A process for preparing antimicrobial copolymers, which comprises
copolymerizing a vinyl ether of the general formula



where R^1 is a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms,
R^2 is H, and
R^3 is H or a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms,

with at least one aliphatically unsaturated monomer.

11. The process as claimed in claim 10, wherein the vinyl ether used comprises 3-aminopropyl vinyl ether.

12. The process as claimed in claim 10 or 11, wherein the aliphatically unsaturated monomers are methacrylic acid compounds.

13. The process as claimed in claim 10 or 11, wherein the aliphatically unsaturated monomers are acrylic acid compounds.

14. The process as claimed in claim 10 or 11, wherein the aliphatically unsaturated monomers used are methyl methacrylate, ethyl methacrylate, butyl methacrylate, tert-butyl methacrylate, methyl acrylate, ethyl acrylate, butyl acrylate, tert-butyl acrylate, tert-butylaminoethyl esters, 2-diethylaminoethyl methacrylate, 2-diethylamino-ethyl vinyl ether, N-3-dimethylaminopropyl-methacrylamide, 3-methacryloylaminopropyltri-methylammonium chloride, 2-methacryloyloxyethyltrimethylammonium chloride or

2-methacryloyloxyethyltrimethylammonium methosulfate.

15. The process as claimed in any one of claims 10 to 14,
wherein
the copolymerization is carried out on a substrate.

16. A process for preparing an antimicrobial coating of a substrate,
which comprises
copolymerizing vinyl ethers of the general formula



where R^1 is a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, and
R^2 and R^3 are H or a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, where R^2 and R^3 may be identical or different,

in graft polymerization of a substrate.

17. The process as claimed in claim 16,
wherein
the substrate is activated prior to the graft polymerization by UV radiation, plasma treatment, corona treatment, flame treatment, ozonization, electrical discharge or γ-radiation.

18. The process as claimed in claim 16, wherein the substrate is activated prior to the graft polymerization by UV radiation with a photoinitiator.

19. The use of the antimicrobial polymers as claimed in any of claims 1 to 9 for producing products with an antimicrobial coating of the polymer.

20. The use of the antimicrobial polymers as claimed in any one of claims 1 to 9 for producing medical items with an antimicrobial coating of the polymer.

21. The use of the antimicrobial polymers as claimed in any one of claims 1 to 9 for producing hygiene items with an antimicrobial coating of the polymer.

22. The use of the antimicrobial polymers as claimed in any one of claims 1 to 9 in surface coatings, protective paints or other coatings.

Copolymers of aminopropyl vinyl ether

The invention relates to antimicrobial polymers obtained by copolymerizing aminofunctionalized vinyl ethers with other monomers. The invention further relates to a process for preparing these antimicrobial polymers, and to their use.

The invention further relates to antimicrobial polymers obtained by a graft copolymerization of aminofunctionalized vinyl ethers with other monomers on a substrate, and also to a process for the preparation of the graft copolymers, and to their use.

It is highly undesirable for bacteria to become established or to spread on the surfaces of pipelines, containers or packaging. Frequently, slime layers form and permit sharp rises in microbial populations, and these can lead to persistent impairment of the quality of water, drinks or foods, and even to spoilage of the product and harm to the health of consumers.

Bacteria must be kept away from all areas of life in which hygiene is important. This affects textiles for direct body contact, especially in the genital area, and for the care of the elderly and sick. Bacteria must also be kept away from surfaces of furniture and instruments in wards, especially in areas for intensive care and neonatal care, in hospitals, especially in areas for medical interventions, and in isolation wards for critical cases of infection, and also in toilets.

A current method of treating equipment, or the surfaces of furniture or textiles, to resist bacteria, either when this becomes necessary or else as a precautionary measure, is to use chemicals or solutions or mixtures of these which as disinfectants have fairly broad and general antimicrobial action. Chemical agents of this type act nonspecifically and are frequently themselves toxic or irritant, or form degradation products which are hazardous to health. In addition, people frequently exhibit intolerance to these materials once they have become sensitized.

Another method to counteract surface spread of bacteria is to incorporate substances with antimicrobial action into a matrix.

tert-Butylaminoethyl methacrylate is a commercially available monomer in methacrylate chemistry and is used in particular as a hydrophilic constituent in copolymerizations. For example, EP-B 0 290 676 describes the use of various polyacrylates and polymethacrylates as a matrix for immobilizing bactericidal quaternary ammonium compounds.

In another technical sector US-A 4 532 269 discloses a terpolymer of butyl methacrylate, tributyltin methacrylate and tert-butylaminoethyl methacrylate. This polymer is used as an antimicrobial paint for ships: the hydrophilic tert-butylaminoethyl methacrylate promotes gradual erosion of the polymer, thus liberating the highly toxic tributyltin methacrylate as antimicrobial agent.

In these applications the copolymer prepared using aminomethacrylates is merely a matrix or carrier substance for added microbicidal agents which can diffuse or migrate out of the carrier substance. Sooner or later, polymers of this type lose their effectiveness once the "minimal inhibitory concentration" (MIC) is no longer achieved on the surface.

European Patent Applications 0 862 858 and 0 862 859 have disclosed that homo- and copolymers of tert-butylaminoethyl methacrylate, a methacrylate having a secondary amino function, have inherent microbicidal properties. To avoid undesirable resistance phenomena in the microbes, particularly bearing in mind the development of resistance by bacteria known from antibiotics research, systems developed in the future will also have to be based on novel compositions with improved effectiveness.

The object of the present invention is therefore to develop novel polymers having antimicrobial action which prevent the establishment and spread of bacteria on surfaces.

Surprisingly, it has now been found that copolymerizing aminofunctionalized vinyl ethers with aliphatically unsaturated monomers and, respectively, a graft copolymerization of these components on a substrate gives polymers with a surface which is durably microbicidal,

resists solvents and physical stresses and does not exhibit migration. This means that there is no need for other biocides to be used.

3-Aminopropyl vinyl ether is a commercially available product whose preparation can be found, for example, in the European Patent Application 0 514 710. It is used, inter alia, as an additive for photoresist systems, described, for example, in US 5648194, or as an element in the structure of adhesion promoters in specific urethane-silanes, described, for example, in US 5384342. The use of compounds of this type in antimicrobial polymers is not known.

The present invention therefore provides antimicrobial copolymers which are obtained by copolymerizing a vinyl ether of the general formula



where R^1 is a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, and

R^2 and R^3 are H or a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, where R^2 and R^3 may be identical or different,

with at least one aliphatically unsaturated monomer.

The proportion of vinyl ethers in the reaction mixture should be from 5 to 98 mol%, preferably from 30 to 98 mol%, particularly preferably from 50 to 98 mol%, based on the total of the monomers, in order to obtain sufficient antimicrobial action from the polymer.

The aliphatically unsaturated monomers used may be any monomers which enter into copolymerization with the vinyl ethers of the general

formula. Examples of suitable monomers are acrylates or methacrylates, such as acrylic acid, tert-butyl methacrylate or methyl methacrylate, styrene, vinyl chloride, vinyl ethers, acrylamides, acrylonitriles, olefins (ethylene, propylene, butylene or isobutylene), allyl compounds, vinyl ketones, vinyl acetic acid, vinyl acetate or vinyl esters, in particular, for example, methyl methacrylate, ethyl methacrylate, butyl methacrylate, tert-butyl methacrylate, methyl acrylate, ethyl acrylate, butyl acrylate, tert-butyl acrylate, tert-butylaminoethyl esters, 2-diethylaminoethyl methacrylate, 2-diethylaminoethyl vinyl ether, N-3-diethylaminopropylmethacrylamide, 3-methacryloylaminopropyltrimethylammonium chloride, 2-methacryloyloxyethyltrimethylammonium chloride or 2-methacryloyloxyethyltrimethylammonium methosulfate.

The aliphatically unsaturated monomers are preferably acrylic acid compounds or methacrylic acid compounds, and the vinyl ethers of the general formula are preferably 3-aminopropyl vinyl ether.

The novel antimicrobial copolymers may be obtained by copolymerizing vinyl ethers of the general formula, in particular 3-aminopropyl vinyl ethers with one or more aliphatically unsaturated monomers. The polymerization is usefully a free-radical polymerization using a free-radical initiator or induced by radiation. Typical procedures are described in the examples.

The novel antimicrobial copolymers may also be obtained by copolymerizing vinyl ethers of the general formula, in particular 3-aminopropyl vinyl ether with at least one aliphatically unsaturated monomer on a substrate. This gives a physisorbed coating of the antimicrobial copolymer on the substrate.

Suitable substrate materials are especially any of the polymeric plastics, such as polyurethanes, polyamides, polyesters or polyethers, polyether block amides, polystyrene, polyvinyl chloride, polycarbonates, poly-organosiloxanes, polyolefins, polysulfones, polyisoprene, polychloroprene, polytetrafluoroethylene (PTFE) or corresponding copolymers or blends, or else naturally occurring or synthetic rubbers, with or without radiation-sensitive groups. The novel process may also be used on the surfaces of objects made from metal, from glass or from wood and surface-coated or otherwise coated with plastic.

In another embodiment of the present invention the copolymers may be prepared by a graft polymerization of a substrate with vinyl ethers of the general formula and with at least one aliphatically unsaturated monomer. The grafting of the substrate allows covalent linking of the antimicrobial copolymer to the substrate. Substrates which may be used are any polymeric material, such as the plastics mentioned above.

Prior to the graft copolymerization, the surfaces of the substrate may be activated by a variety of methods. Any standard method for activating polymer surfaces may be used here, for example the substrate may be activated prior to the graft polymerization by UV radiation, plasma treatment, corona treatment, flame treatment, ozonization, electrical discharge or γ-radiation. The surfaces are usefully freed in advance in a known manner from oils, fats or other contamination, using a solvent.

The substrates may be activated using UV radiation in the wavelength range from 170 to 400 nm, preferably from 170 to 250 nm. An example of a suitable radiation source is a Noblelight UV excimer apparatus from HERAEUS, Hanau, Germany. However, mercury vapor lamps are also suitable for substrate activation as long as they emit substantial proportions of radiation in the abovementioned ranges. The exposure time is generally from 0.1 seconds to 20 minutes, preferably from 1 second to 10 minutes.

The activation of the substrate with UV radiation prior to the graft polymerization may also be done using an additional photosensitizer. For this, the photosensitizer, such as benzophenone, is applied to the substrate surface and irradiated. A mercury vapor lamp may again be used here, with exposure times of from 0.1 second to 20 minutes, preferably from 1 second to 10 minutes.

According to the invention, the activation may also be achieved by plasma treatment using an RF or microwave plasma (Hexagon, Technics Plasma, 85551 Kirchheim, Germany) in air, nitrogen or argon atmospheres. The exposure times are generally from 2 seconds to 30 minutes, preferably from 5 seconds to 10 minutes. The energy supplied in the case of laboratory devices is from 100 to 500 W, preferably from 200 to 300 W.

Corona devices (SOFTAL, Hamburg, Germany) may also be used for activation. The exposure times in this case are generally from 1 to 10 minutes, preferably from 1 to 60 seconds.

Activation by electrical discharge, electron beam or γ-radiation (e.g. from a cobalt 60 source), and also ozonization, allows short exposure times, generally from 0.1 to 60 seconds.

Substrate surfaces may also be activated by flame treatment. Suitable devices, in particular those with a barrier flame front, can readily be constructed or, for example, purchased from ARCOTEC, 71297 Mönsheim, Germany. They may be operated using hydrocarbons or hydrogen as combustion gas. In all cases it is necessary to avoid damage to the substrate by overheating, and this can readily be ensured if the surface of the substrate facing away from the flame treatment side is in intimate contact with a cooled metal surface. Activation by flame treatment is therefore restricted to relatively thin, sheet-like substrates. The exposure times are generally from 0.1 second to 1 minute, preferably from 0.5 to 2 seconds. The flames are exclusively nonluminous, and the distances between the substrate surfaces and the outer side of the flame front are from 0.2 to 5 cm, preferably from 0.5 to 2 cm.

The substrate surfaces activated in this way are coated by known methods, such as dipping, spraying or spreading, with vinyl ethers of the general formula (component I), in particular with 3-aminopropyl vinyl ether, and with one or more aliphatically unsaturated monomers (component II), in solution if desired. Solvents which have proven useful are water and water/ethanol mixtures, but other solvents may also be used as long as they are sufficiently capable of dissolving the monomers and give good wetting of the substrate surfaces. Solutions with monomer contents of from 1 to 10% by weight, for example about 5% by weight, have proven successful in practice and generally give, in a single pass, coherent coatings which cover the substrate surface and have thicknesses which can be more than 0.1 μm.

The graft copolymerization of the monomers applied to the activated surfaces may usefully be initiated by radiation in the short-wave segment of the visible range or in the long-wave segment of the UV range of electromagnetic radiation. For example, the radiation from a UV excimer of

wavelengths from 250 to 500 nm, preferably from 290 to 320 nm, is very suitable. Mercury vapor lamps are also suitable here as long as they have substantial proportions of radiation in the abovementioned ranges. The exposure times are generally from 10 seconds to 30 minutes, preferably from 2 to 15 minutes.

A graft copolymerization of the novel comonomer compounds can also be achieved by a process described in European Patent Application 0 872 512 and based on a graft polymerization of monomer molecules and initiator molecules incorporated by swelling. The monomer used for the swelling may be component II.

Even without grafting onto a substrate surface, the novel antimicrobial copolymers of vinyl ethers of the general formula (component I), in particular 3-aminopropyl vinyl ether with at least one aliphatically unsaturated monomer (component II) show microbicidal or antimicrobial behaviour. Another embodiment of the present invention consists in carrying out the copolymerization of components I and II on a substrate.

The components may be in solution when applied to the substrate. Examples of suitable solvents are water, ethanol, methanol, methyl ethyl ketone, diethyl ether, dioxane, hexane, heptane, benzene, toluene, chloroform, dichloromethane, tetrahydrofuran and acetonitrile. It is also possible to use component II as solvent for component I.

The novel antimicrobial copolymers may also be used directly, i.e. not by polymerizing the components on a substrate but as an antimicrobial coating. Suitable coating methods are application of the copolymers in solution or as a melt.

The solution of the novel polymers may be applied to the substrates by dipping, spraying or painting, for example.

If the novel polymers are used directly on the substrate surface without grafting, conventional free-radical initiators may be added. Examples of initiators which may be used in the preparation of the novel copolymers are, inter alia, azonitriles, alkyl peroxides, hydroperoxides, acyl peroxides, peroxoketones, peresters, peroxocarbonates, peroxodisulfate, persulfate and any of the usual photoinitiators, such as acetophenones, α-

hydroxyketones, dimethylketals and benzophenone. The polymerization may also be initiated thermally or, as already stated, by electromagnetic radiation, such as UV light or γ-radiation.

The novel antimicrobial polymers may also be used as components for formulating inks, paints or other surface coatings.

Use of the modified polymer substrates

The present invention also provides the use of the novel antimicrobial polymers to produce antimicrobially active products, and the products per se which are produced in this way. The products may comprise polymer substrates modified according to the invention or consist of these. Products of this type are preferably based on polyamides, polyurethanes, polyether block amides, polyesteramides or -imides, PVC, polyolefins, silicones, polysiloxanes, polymethacrylate or poly-terephthalates which are surface-modified using novel polymers.

Examples of antimicrobially active products of this type are in particular machine parts for food processing, components in air-conditioning systems, roofing, items for bathroom and toilet use, kitchen items, components of sanitary equipment, components of cages or houses for animals, recreational products for children, components of water systems, food packaging, operator units (touch panels) of devices, and contact lenses.

The novel copolymers or graft copolymers may be used anywhere where importance is placed on surfaces with release properties or surfaces which are very free from bacteria, i.e. microbicidal. Examples of application of the novel copolymers or graft polymers are in particular surface coatings, protective paints and other coatings in the following sectors:

- Marine: Boat hulls, docks, buoys, drilling platforms, ballast water tanks
- Construction: Roofing, basements, walls, facades, greenhouses, sun protection, garden fencing, wood protection
- Sanitary: Public conveniences, bathrooms, shower curtains, toilet items, swimming pool, sauna, jointing, sealing compounds

- Requisites for daily life: Machines, kitchen, kitchen items, sponge pads, recreational products for children, food packaging, milk processing, drinking water systems, cosmetics
- Machine parts: Air-conditioning systems, ion exchangers, process water, solar-powered units, heat exchangers, bioreactors, membranes
- Medical technology: Contact lenses, diapers, membranes, implants
- Consumer articles: Automobile seats, clothing (socks, sports clothing), hospital equipment, door handles, telephone handsets, public conveyances, animal cages, cash registers, wall-to-wall carpets, wallpapers.

The present invention also provides for the use of the novel polymer substrates, whose surfaces have been modified using novel polymers or processes, for producing hygiene products or items in medical technology. That which has been said above concerning preferred materials applies correspondingly. Examples of hygiene products of this type are toothbrushes, toilet seats, combs and packaging materials. The term hygiene item also includes other objects which may come into contact with a large number of people, such as telephone handsets, stair rails, door handles, window catches, and grab straps and grab handles in public conveyances. Examples of items in medical technology are catheters, tubing, protective or backing films and also surgical instruments.

The following examples are given in order to describe the present invention in greater detail, but are not intended to limit its scope as set out in the patent claims.

Example 1:

6 g of 3-aminopropyl vinyl ether (Aldrich), 6 g of methyl methacrylate (Aldrich) and 60 ml of ethanol are charged to a three-necked flask and heated to 65°C under a stream of argon. 0.15 g of azobisisobutyronitrile dissolved in 4 ml of ethyl methyl ketone is then slowly added dropwise, with stirring. The mixture is heated to 70°C and stirred at this temperature for 72 h. After expiry of this time the reaction mixture is stirred into 0.5 l of deionized water, whereupon the polymeric product precipitates. After filtering off the product, the filter cake is washed with 100 ml of deionized water to remove any monomer residues still present. The product is then dried in vacuo for 24 hours at 50°C.

Example 1a:

0.05 g of the product from Example 1 is shaken in 20 ml of a test microbial suspension of Staphylococcus aureus. After a contact time of 15 minutes, 1 ml of the test microbial suspension is removed, and the number of microbes in the test mixture is determined. After expiry of this time Staphylococcus aureus microbes are no longer detectable.

Example 1b:

0.05 g of the product from Example 1 is shaken in 20 ml of a test microbial suspension of Pseudomonas aeruginosa. After a contact time of 60 minutes, 1 ml of the test microbial suspension is removed, and the number of microbes in the test mixture is determined. After expiry of this time the number of microbes has reduced from 10^7 to 10^2.

Example 2:

6 g of 3-aminopropyl vinyl ether (Aldrich), 6 g of butyl methacrylate (Aldrich) and 60 ml of ethanol are charged to a three-necked flask and heated to 65°C under a stream of argon. 0.15 g of azobisisobutyronitrile dissolved in 4 ml of ethyl methyl ketone is then slowly added dropwise, with stirring. The mixture is heated to 70°C and stirred at this temperature for 72 h. After expiry of this time the reaction mixture is stirred into 0.5 l of deionized water, whereupon the polymeric product precipitates. After filtering off the product, the filter cake is washed with 100 ml of deionized water to remove any monomer residues still present. The product is then dried in vacuo for 24 hours at 50°C.

Example 2a:

0.05 g of the product from Example 2 is shaken in 20 ml of a test microbial suspension of Staphylococcus aureus. After a contact time of 15 minutes, 1 ml of the test microbial suspension is removed, and the number of microbes in the test mixture is determined. After expiry of this time Staphylococcus aureus microbes are no longer detectable.

Example 2b:

0.05 g of the product from Example 2 is shaken in 20 ml of a test microbial suspension of Pseudomonas aeruginosa. After a contact time of 60 minutes, 1 ml of the test microbial suspension is removed, and the number of microbes in the test mixture is determined. After expiry of this time the number of microbes has reduced from 10^7 to 10^2.

Example 3:

6 g of 3-aminopropyl vinyl ether (Aldrich), 6 g of 2-diethylaminoethyl methacrylate (Aldrich) and 60 ml of ethanol are charged to a three-necked flask and heated to 65°C under a stream of argon. 0.15 g of azobisisobutyronitrile dissolved in 4 ml of ethyl methyl ketone is then slowly added dropwise, with stirring. The mixture is heated to 70°C and stirred at this temperature for 72 h. After expiry of this time the reaction mixture is stirred into 0.5 l of deionized water, whereupon the polymeric product precipitates. After filtering off the product, the filter cake is washed with 100 ml of deionized water to remove any monomer residues still present. The product is then dried in vacuo for 24 hours at 50°C.

Example 3a:

0.05 g of the product from Example 3 is shaken in 20 ml of a test microbial suspension of Staphylococcus aureus. After a contact time of 15 minutes, 1 ml of the test microbial suspension is removed, and the number of microbes in the test mixture is determined. After expiry of this time the number of microbes has reduced from 10^7 to 10^2.

Example 3b:

0.05 g of the product from Example 3 is shaken in 20 ml of a test microbial suspension of Pseudomonas aeruginosa. After a contact time of 60 minutes, 1 ml of the test microbial suspension is removed, and the number of microbes in the test mixture is determined. After expiry of this time the number of microbes has reduced from 10^7 to 10^2.

Example 4:

6 g of 3-aminopropyl vinyl ether (Aldrich), 6 g of tert-butyl methacrylate (Aldrich) and 60 ml of ethanol are charged to a three-necked flask and heated to 65°C under a stream of argon. 0.15 g of azobisisobutyronitrile dissolved in 4 ml of ethyl methyl ketone is then slowly added dropwise, with stirring. The mixture is heated to 70°C and stirred at this temperature for 72 h. After expiry of this time the reaction mixture is stirred into 0.5 l of deionized water, whereupon the polymeric product precipitates. After filtering off the product, the filter cake is washed with 100 ml of deionized water to remove any monomer residues still present. The product is then dried in vacuo for 24 hours at 50°C.

Example 4a:

0.05 g of the product from Example 4 is shaken in 20 ml of a test microbial suspension of Staphylococcus aureus. After a contact time of 15 minutes, 1 ml of the test microbial suspension is removed, and the number of microbes in the test mixture is determined. After expiry of this time Staphylococcus aureus microbes are no longer detectable.

Example 4b:

0.05 g of the product from Example 4 is shaken in 20 ml of a test microbial suspension of Pseudomonas aeruginosa. After a contact time of 60 minutes, 1 ml of the test microbial suspension is removed, and the number of microbes in the test mixture is determined. After expiry of this time the number of microbes has reduced from 10^7 to 10^2.

Example 5:

A nylon-12 film is exposed for 2 minutes at a pressure of 1 mbar to 172 nm radiation from a Heraeus excimer source. The film activated in this way is placed into an irradiator under an inert gas and secured. Under a counterstream of inert gas, the film is then covered with 20 ml of a mixture of 6 g of 3-aminopropyl vinyl ether (Aldrich), 6 g of butyl methacrylate (Aldrich) and 60 g of ethanol. The irradiation chamber is sealed and placed at a distance of 10 cm from a Heraeus excimer source emitting at wavelength 308 nm. Irradiation is begun and continues for 15 minutes. The film is then removed and rinsed with 30 ml of ethanol. The film is then dried for 12 hours at 50°C in vacuo. The film is then extracted in water for 5 times 6 hours at 30°C, then dried for 12 hours at 50°C.

The reverse side of the film is then treated in the same way, so that the nylon film finally obtained has been coated on both sides with grafted polymer.

Example 5a:

A piece of coated film from Example 5 (5 x 4 cm) is shaken in 30 ml of a test microbial suspension of Staphylococcus aureus. After a contact time of 15 minutes, 1 ml of the test microbial suspension is removed and the number of microbes in the test mixture is determined. After expiry of this time Staphylococcus aureus microbes are no longer detectable.

Example 5b:

A piece of coated film from Example 5 (5 x 4 cm) is shaken in 30 ml of a test microbial suspension of Pseudomonas aeruginosa. After a contact time of 60 minutes, 1 ml of the test microbial suspension is removed and the number of microbes in the test mixture is determined. After expiry of this time the number of microbes has reduced from 10^7 to 10^4.

Example 6:

A nylon-12 film is exposed for 2 minutes at a pressure of 1 mbar to 172 nm radiation from a Heraeus excimer source. The film activated in this way is placed into an irradiator under an inert gas and secured. Under a counterstream of inert gas, the film is then covered with 20 ml of a mixture of 6 g of 3-aminopropyl vinyl ether (Aldrich), 4 g of tert-butyl methacrylate (Aldrich) and 60 g of ethanol. The irradiation chamber is sealed and placed at a distance of 10 cm from a Heraeus excimer source emitting at wavelength 308 nm. Irradiation is begun and continues for 15 minutes. The

film is then removed and rinsed with 30 ml of ethanol. The film is then dried for 12 hours at 50°C in vacuo. The film is then extracted in water for 5 times 6 hours at 30°C, then dried for 12 hours at 50°C.
The reverse side of the film is then treated in the same way, so that the nylon film finally obtained has been coated on both sides with grafted polymer.

Example 6a:

A piece of coated film from Example 6 (5 x 4 cm) is shaken in 30 ml of a test microbial suspension of Staphylococcus aureus. After a contact time of 15 minutes, 1 ml of the test microbial suspension is removed and the number of microbes in the test mixture is determined. After expiry of this time Staphylococcus aureus microbes are no longer detectable.

Example 6b:

A piece of coated film from Example 6 (5 x 4 cm) is shaken in 30 ml of a test microbial suspension of Pseudomonas aeruginosa. After a contact time of 60 minutes, 1 ml of the test microbial suspension is removed and the number of microbes in the test mixture is determined. After expiry of this time the number of microbes has reduced from 10^7 to 10^4.

What is claimed is:

1. An antimicrobial copolymer, obtainable by copolymerizing a vinyl ether of the general formula



where R^1 is a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, and
R^2 and R^3 are H or a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, where R^2 and R^3 may be identical or different,

with at least one aliphatically unsaturated monomer.

2. An antimicrobial polymer as claimed in claim 1, wherein the vinyl ether used comprises 3-aminopropyl vinyl ether.

3. An antimicrobial polymer as claimed in claim 1 or 2, wherein the aliphatically unsaturated monomers are methacrylic acid compounds.

4. An antimicrobial polymer as claimed in claim 1 or 2, wherein the aliphatically unsaturated monomers are acrylic acid compounds.

5. An antimicrobial polymer as claimed in claim 1 or 2, wherein

the aliphatically unsaturated monomers used are methyl methacrylate, ethyl methacrylate, butyl methacrylate, tert-butyl methacrylate, methyl acrylate, ethyl acrylate, butyl acrylate, tert-butyl acrylate, tert-butylaminoethyl esters, 2-diethylaminoethyl methacrylate, 2-diethylaminoethyl vinyl ether, N-3-dimethylamino-propylmethacrylamide, 3-methacryloylaminopropyl-trimethylammonium chloride, 2-methacryloyloxyethyltrimethylammonium chloride or 2-methacryloyloxyethyltrimethylammonium methosulfate.

6. An antimicrobial polymer as claimed in any one of claims 1 to 5, wherein
the copolymerization is carried out on a substrate.

7. An antimicrobial polymer as claimed in any one of claims 1 to 5, wherein
the copolymerization is carried out as a graft polymerization of a substrate.

8. An antimicrobial polymer as claimed in claim 7, wherein
the substrate is activated prior to the graft polymerization by UV radiation, plasma treatment, corona treatment, flame treatment, ozonization, electrical discharge or γ-radiation.

9. An antimicrobial polymer as claimed in claim 7, wherein
the substrate is activated, prior to the graft polymerization, by UV radiation with a photoinitiator.

10. A process for preparing antimicrobial copolymers, which comprises
copolymerizing a vinyl ether of the general formula



where R^1 is a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, and

R^2 and R^3 are H or a branched or unbranched hydrocarbon radical having from 1 to 5 carbon atoms, where R^2 and R^3 may be identical or different,

with at least one aliphatically unsaturated monomer.

11. The process as claimed in claim 10, wherein the vinyl ether used comprises 3-aminopropyl vinyl ether.

12. The process as claimed in claim 10 or 11, wherein the aliphatically unsaturated monomers are methacrylic acid compounds.

13. The process as claimed in claim 10 or 11, wherein the aliphatically unsaturated monomers are acrylic acid compounds.

14. The process as claimed in claim 10 or 11, wherein the aliphatically unsaturated monomers used are methyl methacrylate, ethyl methacrylate, butyl methacrylate, tert-butyl methacrylate, methyl acrylate, ethyl acrylate, butyl acrylate, tert-butyl acrylate, tert-butylaminoethyl esters, 2-diethylaminoethyl methacrylate, 2-diethylaminoethyl vinyl ether, N-3-dimethylaminopropyl-methacrylamide, 3-methacryloylaminopropyltri-methylammonium chloride, 2-

methacryloyloxyethyltrimethylammonium chloride or 2-methacryloyloxyethyltrimethylammonium methosulfate.

15. The process as claimed in any one of claims 10 to 14, wherein the copolymerization is carried out on a substrate.

16. The process as claimed in any one of claims 10 to 14, wherein the copolymerization is carried out as a graft polymerization of a substrate.

17. The process as claimed in claim 16, wherein the substrate is activated prior to the graft polymerization by UV radiation, plasma treatment, corona treatment, flame treatment, ozonization, electrical discharge or γ-radiation.

18. The process as claimed in claim 16, wherein the substrate is activated prior to the graft polymerization by UV radiation with a photoinitiator.

19. The use of the antimicrobial polymers as claimed in any of claims 1 to 9 for producing products with an antimicrobial coating of the polymer.

20. The use of the antimicrobial polymers as claimed in any one of claims 1 to 9 for producing medical items with an antimicrobial coating of the polymer.

21. The use of the antimicrobial polymers as claimed in any one of claims 1 to 9 for producing hygiene items with an antimicrobial coating of the polymer.

22. The use of the antimicrobial polymers as claimed in any one of claims 1 to 9 in surface coatings, protective paints or other coatings.

Abstract:

The invention relates to antimicrobial polymers obtained by copolymerizing vinyl ethers of the general formula



in particular 3-aminopropyl vinyl ether, with other aliphatically unsaturated monomers, and to a process for their preparation.

The polymers may also be prepared by a graft copolymerization of a substrate, giving a covalently bonded coating on the substrate surface.

The antimicrobial polymers may be used as a microbicidal coating, inter alia on hygiene items or in the medical sector, or else in surface coatings or protective paints.

Declaration and Power of Attorney For Patent Application
Erklärung Für Patentanmeldungen Mit Vollmacht
German Language Declaration

Als nachstehend benannter Erfinder erkläre ich hiermit an Eides Statt:

As a below named inventor, I hereby declare that:

dass mein Wohnsitz, meine Postanschrift, und meine Staatsangehörigkeit den im Nachstehenden nach meinem Namen aufgeführten Angaben entsprechen,

My residence, post office address and citizenship are as stated below next to my name,

dass ich, nach bestem Wissen der ursprüngliche, erste und alleinige Erfinder (falls nachstehend nur ein Name angegeben ist) oder ein ursprünglicher, erster und Miterfinder (falls nachstehend mehrere Namen aufgeführt sind) des Gegenstandes bin, für den dieser Antrag gestellt wird und für den ein Patent beantragt wird für die Erfindung mit dem Titel:

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

COPOLYMERS OF AMINOPROPYL VINYL ETHER

deren Beschreibung

(zutreffendes ankreuzen)

☐ hier beigefügt ist.

☐ am _____ unter der

Anmeldungsseriennummer _____

eingereicht wurde und am _____.
abgeändert wurde (falls tatsächlich abgeändert).

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on July 08, 2000 as

Application Serial No. PCT/EP00/06506

and was amended on _____.
(if applicable)

Ich bestätige hiermit, dass ich den Inhalt der obigen Patentanmeldung einschliesslich der Ansprüche durchgesehen und verstanden habe, die eventuell durch einen Zusatzantrag wie oben erwähnt abgeändert wurde.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

Ich erkenne meine Pflicht zur Offenbarung irgendwelcher Informationen, die für die Prüfung der vorliegenden Anmeldung in Einklang mit Absatz 37, Bundesgesetzbuch, Paragraph 1.56(a) von Wichtigkeit sind, an.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

Ich beanspruche hiermit ausländische Prioritätsvorteile gemäss Abschnitt 35 der Zivilprozessordnung der Vereinigten Staaten, Paragraph 119 aller unten angegebenen Auslandsanmeldungen für ein Patent oder eine Erfindersurkunde, und habe auch alle Auslandsanmeldungen für ein Patent oder eine Erfindersurkunde nachstehend gekennzeichnet, die ein Anmeldedatum haben, das vor dem Anmeldedatum der Anmeldung liegt, für die Priorität beansprucht wird.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

German Language Declaration

Ich beanspruche hiermit ausländische Prioritätsvorteile gemäß Title 35, US-Code, § 119(a)-(d), bzw. § 365(b) aller unten aufgeführten Auslandsanmeldungen für Patente oder Erfinderurkunden, oder § 365(a) aller PCT internationalen Anmeldungen, welche wenigstens ein Land ausser den Vereinigten Staaten von Amerika benennen, und habe nachstehend durch ankreuzen sämtliche Auslandsanmeldungen für Patente bzw. Erfinderurkunden oder PCT internationale Anmeldungen angegeben, deren Anmeldetag dem der Anmeldung, für welche Priorität beansprucht wird, vorangeht.

I hereby claim foreign priority under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below, and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior foreign application(s) (Frühere ausländische Anmeldungen) (Number) (Nummer)	(Country) (Land)	(Day/Month/Year Filed) (Tag/Monat/Jahr der Anmeldung)	Priority claimed Priorität beansprucht Yes Ja	No Nein
199 40 023.7	Germany	24/AUGUST/1999	☒	☐
			☐	☐

Ich Beanspruche hiermit Prioritätsvorteile unter Title 35, US-Code, § 119(e) aller US-Hilfsanmeldungen wie unten aufgezählt.

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

(Application No.) (Aktenzeichen)	(Filing Date) (Anmeldetag)	(Application No.) (Aktenzeichen)	(Filing Date) (Anmeldetag)

Ich beanspruche hiermit die mir unter Title 35, US-Code, § 120 zustehenden Vorteile aller unten aufgeführten US-Patentanmeldungen bzw. § 365(c) aller PCT internationalen Anmeldungen, welche die Vereinigten Staaten von Amerika benennen, und erkenne, insofern der Gegenstand eines jeden früheren Anspruchs dieser Patentanmeldung nicht in einer US-Patentanmeldung, bzw. PCT internationalen Anmeldung in in einer gemäß dem ersten Absatz von Title 35, US-Code, § 112 vorgeschriebenen Art und Weise offenbart wurde, meine Pflicht zur Offenbarung jeglicher Informationen an, die zur Prüfung der Patentfähigkeit in Einklang mit Title 37, Code of Federal Regulations, § 1.56 von Belang sind und die im Zeitraum zwischen dem Anmeldetag der früheren Patentanmeldung und dem nationalen oder im Rahmen des Vertrags über die Zusammenarbeit auf dem Gebiet des Patentwesen (PCT) gültigen internationalen Anmeldetags bekannt geworden sind.

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(Application No.) (Aktenzeichen)	(Filing Date) (Anmeldetag)	(Status) (patented, pending, abandoned) (Status) (patentiert, schwebend, aufgegeben)
PCT/EP00/06506	July 8, 2000	pending

Ich erkläre hiermit, daß alle in der vorliegenden Erklärung von mir gemachten Angaben nach bestem Wissen und Gewissen der Wahrheit entsprechen, und ferner daß ich diese eidesstattliche Erklärung in Kenntnis dessen ablege, daß wissentlich und vorsätzlich falsche Angaben oder dergleichen gemäß § 1001, Title 18 des US-Code strafbar sind und mit Geldstrafe und/oder Gefängnis bestraft werden können und daß derartige wissentlich und vorsätzlich falsche Angaben die Rechtswirksamkeit der vorliegenden Patentanmeldung oder eines aufgrund deren erteilten Patentes gefährden können.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

5475-0101

German Language Declaration

VERTRETUNGSVOLLMACHT: Als benannter Erfinder beauftrage ich hiermit den nachstehend benannten Patentanwalt (oder die nachstehend bennanten Patentanwälte) und/oder Patent-Agenten mit der Verfolgung der vorliegenden Patentanmeldung sowie mit der Abwicklung aller damit verbundenen Geschäfte vor dem Patent-und Warenzeichenamt: *(Name und Registrationsnummer anführen)*

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

30

Norman F. Oblon, Registration Number 24,618; Marvin J. Spivak, Registration Number 24,913; C. Irvin McClelland, Registration Number 21,124; Gregory J. Maier, Registration Number 25,599; Arthur I. Neustadt, Registration Number 24,854; Richard D. Kelly, Registration Number 27,757; James D. Hamilton, Registration Number 28,421; Eckhard H. Kuesters, Registration Number 28,870; Robert T. Pous, Registration Number 29,099; Charles L. Gholz, Registration Number 26,395; Vincent J. Sunderdick, Registration Number 29,004; William E. Beaumont, Registration Number 30,996; Steven B. Kelber, Registration Number 30,073; Robert F. Gnuse, Registration Number 27,295; Jean-Paul Lavalleye, Registration Number 31,451; Stephen G. Baxter, Registration Number 32,884; Martin M. Zoltick, Registration Number 35,745; Robert W. Hahl, Registration Number 33,893; Richard L. Treanor, Registration Number 36,379; Steven P. Weihrouch, Registration Number 32,829; John T. Goolkasian, Registration Number 26,142; Marc R. Labgold, Registration Number 34,651; William J. Healey, Registration Number 36,160; Richard L. Chinn, Registration Number 34,305; Steven E. Lipman, Registration Number 30,011; Carl E. Schlier, Registration Number 34,426; James J. Kulbaski, Registration Number 34,648; Catherine B. Richardson, Registration Number 39,007; Richard A. Neifeld, Registration Number 35,299; and J. Derek Mason, Registration Number 35,270; with full powers of substitution and revocation.

Telefongespräche bitte richten an: *(Name und Telefonnummer)*

Direct Telephone Calls to: *(name and telephone number)*

(703) 413-3000

Postanschrift:

Send Correspondence to:

OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
FOURTH FLOOR
1755 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VIRGINIA 22202 U.S.A.

Voller Name des einzigen oder ursprünglichen Erfinders: 1-00	Full name of sole or first inventor: Peter OITTERSBACH
Unterschrift des Erfinders Datum	Inventor's signature Date 06. FEB. 2002
Wohnsitz	Residence Windeck, Germany DEX
Staatsangehörigkeit	Citizenship German
Postanschrift	Post Office Address Zum Beuel 14, 51570 Windeck, Germany
Voller Name des zweiten Miterfinders (falls zutreffend) 2-00	Full name of second joint inventor, if any: Beate KOSSMANN
Unterschrift des Erfinders Datum	Second Inventor's signature Date 06. FEB. 2002
Wohnsitz	Residence Hagen, Germany DEX
Staatsangehörigkeit	Citizenship German
Postanschrift	Post Office Address Ribbertstraße 13, 58091 Hagen, Germany

(Bitte entsprechende informationen und Unterschriften im Falle von dritten und weiteren Miterfindern angeben).

(Supply similar information and signature for third and subsequent joint inventors.)